Food Recipe Collections & Favorites Popular Ingredients Is CBG the Next CBD? Here's What You Should Know Plus a clear breakdown of the differences between CBD, THC, and CBG. By Betty Gold Betty Gold Betty Gold is the former senior digital food editor at Real Simple. Real Simple's Editorial Guidelines Updated on December 30, 2022 Fact checked by Emily Peterson Fact checked by Emily Peterson Emily Peterson is an experienced fact-checker and editor with Bachelor's degrees in English Literature and French. Our Fact-Checking Process Share Tweet Pin Email Photo: Getty Images Chances are, you know at least a little something about CBD. This chemical substance—derived from cannabis plants—is a type of cannabinoid that has a range of possible health-promoting effects. Some CBD gummies, lotions, or oils may even be in your bathroom drawer right now. But you might be less familiar with another cannabinoid, called CBG (short for cannabigerol). Like CBD, this substance is thought to provide healing benefits without altering mood or perception. Most cannabis plants only contain trace amounts of CBG—about 1 percent. But its properties are garnering attention from health professionals and consumers regardless. To better understand CBG and how it differs from CBD, we spoke with Matthew L. Mintz, MD, FACP, an internist and primary care physician practicing in Bethesda, Maryland. He is also a clinical associate professor of medicine at The George Washington University School of Medicine. If You're Curious About CBD, Give This Comprehensive Guide a Read Before You Try It What Is CBG, Exactly? To begin, the term cannabinoid refers to substances that interact with cannabinoid receptors in the human body. Cannabinoids and their receptors are part of our body's system to help regulate a variety of normal functions, including pain, appetite, and inflammation. This system is called the endocannabinoid system (ECS). The human body makes its own cannabinoids (called endocannabinoids). "The body has been doing this for 600 million years,” Dr. Mintz says. The two main cannabinoid receptors in the body are CB1 and CB2, the former more associated with the nervous system and the latter more associated with inflammation. The cannabis plant also produces cannabinoids. “The cannabis plant has only been around for 30 million years but contains hundreds of substances that have biological activities," says Dr. Mintz. "That includes many plant-based cannabinoids, which are called phytocannabinoids.” The 5 Key Questions to Consider When Shopping for CBD Products The two phytocannabinoids that people are most familiar with are cannabidiol (CBD) and tetrahydrocannabinol (THC). “Essentially, plant-based CBD and THC affect the human body by interacting with our CB1 and CB2 receptors," Dr. Mintz says. "In addition to CBD and THC, there are several other phytocannabinoids, and they are all derived from a parent cannabinoid called cannabigerolic acid (CBGA).” CBGA is the precursor to the acidic forms of THC and CBD (called THCA and CBDA). With heat and time, THCA and CBDA get converted to THC and CBD. Both acid and non-acidic (or neutral) cannabinoids have effects on the body. CBG is the non-acidic form of CBGA, and similarly gets converted with time and heat. Differences Between THC, CBD, and CBG Here's the main, important difference between CBD and THC: While THC can make you high, CBD has no psychoactive effects. “The majority of research on CBD by itself has been focused on preventing seizures, and the FDA has recently approved a pharmaceutical-grade CBD for use in severe seizures in children. However, some research shows that CBD can be beneficial for anxiety and inflammation, and may even have anti-cancer properties,” explains Dr. Mintz. CBG is similar to CBD in that it also is non-psychoactive. There is very little research into the effects of CBG on humans. Still, interest is growing. It's thought that different non-psychoactive cannabinoids may have many distinct clinical uses. Potential Benefits of CBG “Animal studies have shown that CBG stimulates receptors involved in pain and heat sensation. It can also stimulate the receptors in the brain and blood vessels that are involved in blood pressure regulation,” says Dr. Mintz. “Thus, CBG might have a role in blood pressure regulation and pain. CBG may have some anti-inflammatory properties as well." Of course, all of these effects are also seen with CBD, so it’s unclear whether or not CBG has any differentiating properties. But there are hints of some future promise. “In regards to specific diseases, there are two animal studies showing that CBG may be beneficial in inflammatory bowel disease (like ulcerative colitis and Crohn's disease) and Huntington's disease (an incurable brain disease). Test tube studies have also shown CBG to have anti-bacterial properties and may prevent colon cancer,” he adds. And CBG may increase dopamine levels as well as support sleep and appetite regulation. CBG has also shown support for the treatment of glaucoma, colon cancer, and MRSA. But more research and clinical studies need to occur before drawing any major conclusions. So what is next for the CBD industry? "We hope to see the industry grow with a mindset for increased access, equity, inclusion, and integrity," says Gabe Kennedy, the co-founder of Plant People. "And we'd like to see investment in regenerative practices, treating people and the planet with respect. CBD is only the tip of the iceberg. There are hundreds of cannabinoids yet to be explored, understood, and utilized." Was this page helpful? Thanks for your feedback! Tell us why! Other Submit Sources Real Simple is committed to using high-quality, reputable sources, including peer-reviewed studies, to support the facts in our articles. Read our editorial guidelines to learn more about how we fact check our content for accuracy. CDC, CBD: What You Need to Know. Accessed December 29, 2022. Perez E, Fernandez JR, Fitzgerald C, et al. In vitro and clinical evaluation of cannabigerol (CBG) produced via yeast biosynthesis: a cannabinoid with a broad range of anti-inflammatory and skin health-boosting properties. Molecules. 2022;27(2):491. doi:10.3390/molecules27020491 Lowe H, Toyang N, Steele B, et al. The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci. 2021;22(17):9472. doi:10.3390/ijms22179472 Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516-525. doi:10.1016/j.biopsych.2015.07.028 National Center for Biotechnology Information, PubChem Compound Summary for CID 6449999, Cannabigerolic acid. Accessed Dec. 30, 2022. Zirpel B, Kayser O, Stehle F. Elucidation of structure-function relationship of THCA and CBDA synthase from Cannabis sativaL. J Biotechnol. 2018;284:17-26. doi:10.1016/j.jbiotec.2018.07.031 Science Direct, Cannabigerolic acid. Accessed December 30, 2022. Jastrząb A, Jarocka-Karpowicz I, Skrzydlewska E. The origin and biomedical relevance of cannabigerol. Int J Mol Sci. 2022;23(14):7929. doi:10.3390/ijms23147929 Kogan NM, Lavi Y, Topping LM, et al. Novel CBG derivatives can reduce inflammation, pain and obesity. Molecules. 2021;26(18):5601. doi:10.3390/molecules26185601 Valdeolivas S, Navarrete C, Cantarero I, et al. Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics. 2015;12(1):185-199. doi:10.1007/s13311-014-0304-z Borrelli F, Fasolino I, Romano B, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013;85(9):1306-1316. doi:10.1016/j.bcp.2013.01.017 Aqawi M, Sionov RV, Gallily R, et al. Anti-bacterial properties of cannabigerol toward streptococcus mutans. Front Microbiol. 2021;12:656471. doi:10.3389/fmicb.2021.656471 Borrelli F, Pagano E, Romano B, et al. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis. 2014;35(12):2787-2797. doi:10.1093/carcin/bgu205 Russo EB, Cuttler C, Cooper ZD, et al. Survey of patients employing cannabigerol-predominant cannabis preparations: perceived medical effects, adverse events, and withdrawal symptoms. Cannabis Cannabinoid Res. 2022;7(5):706-716. doi:10.1089/can.2021.0058 Farha MA, El-Halfawy OM, Gale RT, et al. Uncovering the hidden antibiotic potential of cannabis. ACS Infect Dis. 2020;6(3):338-346. doi:10.1021/acsinfecdis.9b00419 Cairns EA, Baldridge WH, Kelly ME. The endocannabinoid system as a therapeutic target in Glaucoma. Neural Plast. 2016;2016:9364091. doi:10.1155/2016/9364091